Study of ALXN1820 in Healthy Adult Participants

Phase 1 Completed 66 enrolled Alexion Pharmaceuticals, Inc. Syneos Health · collab

RandomizedSequentialDouble-blindBasic science

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of ALXN1820 administered subcutaneously (SC) (ALXN1820 SC) and intravenously (IV) (ALXN1820 IV).

Timeline

Start: 2021-01-13
Primary completion: 2022-09-01
Completion: 2022-09-01

Publications

Sandhu A, Shen T, Herrero PM, Yuan CX, Qureshi S, Jiang X, Sheng Y, Gasteyger C, Dai Y. Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1820 (Tarperprumig) in Healthy Adults: Results of a Phase I Study. Clin Transl Sci. 2025 Apr;18(4):e70190. doi: 10.1111/cts.70190.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tarperprumig	Monoclonal antibody	12.5 mg	Subcutaneous
Subject	Tarperprumig	Monoclonal antibody	50 mg	Subcutaneous
Subject	Tarperprumig	Monoclonal antibody	150 mg	Subcutaneous
Subject	Tarperprumig	Monoclonal antibody	450 mg	Subcutaneous
Subject	Tarperprumig	Monoclonal antibody	1200 mg	Subcutaneous
Subject	Tarperprumig	Monoclonal antibody	2250 mg	Subcutaneous

Indications

No indication recorded.